相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
Nicola De Stefano et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Fingolimod effect on brain volume loss independently contributes to its effect on disability
M. P. Sormani et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
Ernst-Wilhelm Radue et al.
NEUROLOGY (2015)
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
Dalia L. Rotstein et al.
JAMA NEUROLOGY (2015)
Fingolimod effect on brain volume loss independently contributes to its effect on disability
M. P. Sormani et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis
Richard Nixon et al.
ADVANCES IN THERAPY (2014)
Treatment Effect on Brain Atrophy Correlates with Treatment Effect on Disability in Multiple Sclerosis
Maria Pia Sormani et al.
ANNALS OF NEUROLOGY (2014)
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis
Douglas L. Arnold et al.
BMC NEUROLOGY (2014)
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
Nicola De Stefano et al.
CNS DRUGS (2014)
Mechanisms of White Matter Damage in Multiple Sclerosis
Hans Lassmann
GLIA (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study
Eva Havrdova et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Disease Activity Free Status A New End Point for a New Era in Multiple Sclerosis Clinical Research?
Carolyn J. Bevan et al.
JAMA NEUROLOGY (2014)
Randomized study combining interferon and glatiramer acetate in multiple sclerosis
Fred D. Lublin et al.
ANNALS OF NEUROLOGY (2013)
Brain atrophy and lesion load predict long term disability in multiple sclerosis
Veronica Popescu et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
Editors' welcome and a working definition for a multiple sclerosis cure
Brenda Banwell et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2013)
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis
Ernst-Wilhelm Radue et al.
ARCHIVES OF NEUROLOGY (2012)
Association between pathological and MRI findings in multiple sclerosis
Massimo Filippi et al.
LANCET NEUROLOGY (2012)
Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis
Luca Prosperini et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
Gavin Giovannoni et al.
LANCET NEUROLOGY (2011)
MRI predictors of cognitive outcome in early multiple sclerosis
M. S. A. Deloire et al.
NEUROLOGY (2011)
Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis
Richard A. Rudick et al.
ARCHIVES OF NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Josa M. Frischer et al.
BRAIN (2009)
Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis A 5-year longitudinal study
Dana Horakova et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
Eva Havrdova et al.
LANCET NEUROLOGY (2009)
Brain atrophy as an outcome measure for multiple sclerosis clinical trials A no-brainer?
Richard A. Rudick et al.
NEUROLOGY (2009)
Cortical demyelination and diffuse white matter injury in multiple sclerosis
A Kutzelnigg et al.
BRAIN (2005)
Eight-year follow-up study of brain atrophy in patients with MS
E Fisher et al.
NEUROLOGY (2002)
Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts
C Liu et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2000)
分享论文
